Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists have observed the interaction between therapeutic antibodies and their target protein.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/08/200813142347.htm
No comments:
Post a Comment